Investor Presentaiton

10 Investor presentation Full year 2022 Rare disease sales increased by 1% driven by International Operations Reported Rare disease sales Rare disease sales driven by global commercial execution DKK billion Growth at CER 24 1% 7% 6% 18 Rare disease sales increase is driven by: 16% 6% -6% • 5% sales decline in North America Operations 12 Rare blood disorders 6 0 Total1 Rare blood disorders² Haem. A Haem. B Novo- SevenⓇ Rare endocrine disorders³ . . 5% sales growth in International Operations Rare blood disorders sales increased by 7%, driven by: NovoSevenⓇ performance Uptake of launch products EsperoctⓇ and Refixia® Rare endocrine disorders sales decreased by 6% driven by: North America Operations sales declined by 18% driven by supply constraints for Norditropin® and lower realised prices in the US Novo Nordisk is the leading company in the global human growth disorder market with a value market share of -35% 1 Total includes "Other Rare disease", which consists of primarily Vagifem® and Activelle®: 2 Comprises NovoSevenⓇ, Novo Eight®, Esperoct®, RefixiaⓇ and NovoThirteenⓇ; 3 Primarily NorditropinⓇ; Note: NovoThirteenⓇ is not shown for Rare blood disorders breakdown, only for the total bar. Haem. A: Haemophilia A; Haem. B: Haemophilia B; Unless otherwise specified, sales growth is at constant exchange rates Novo NordiskⓇ

View entire presentation